Neurology® Podcast

1) Neurology® Clinical Practice: Medical Marijuana: Between a plant and a hard place and 2) Topic of the month: Updates in tele-neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matthew Wong interviews Dr. David Gloss about his Neurology Clinical Practice paper on medical marijuana: Between a plant and a hard place. Dr. Sarah Wesley is reading our e-Pearl of the week about arterial retinal ischemic disease. In the next part of the podcast Dr. Andy Southerland interviews Dr. Bert Vargas about the topic of teleconcussion. The participants had nothing to disclose except Drs. Gloss, Wesley, Southerland and Vargas.Dr. Gloss serves as an evidence-based medicine consultant for the American Academy of Neurology; serves as an LOE associate editor for Neurology® and receives royalties from the publicationof the book Neurology for the Specialty Boards.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Vargas serves on the scientific advisory boards Allergan, Inc and Zogenix, Inc.; receives honoraria for travel from the American Headache Society.NO CME WILL BE OFFERED THIS WEEK.

1) Pathogenic effects of antibodies on gut and brain neurons in anti-DPPX encephalitis and 2) Topic of the month: Updates in tele-neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michelle Fullard interviews Dr. Johannes Piepgras about his paper on pathogenic effects of antibodies on gut and brain neurons in anti-DPPX encephalitis. Dr. Ted Burns is interviewing Morgan Sorenson for our "What's Trending" feature of the week about twitter handles. In the next part of the podcast Dr. Andy Southerland interviews Dr. Kevin Barrett about the topic of teleneurology (non-stroke applications). The participants had nothing to disclose except Drs. Burns, Sorenson, Southerland and Barrett.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Morgan Sorenson is Managing Editor, Neurology® Neuroimmunology & Neuroinflammation.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Kevin Barrett serves as an Associate Editor of Neurohospitalist; serves as an editorial board member of Neurology; and receives research support from the NIH.

Interviews with Oliver Sacks. Lesson of the Week interviews from January 2011.

1) Neurology® Neuroimmunology & Neuroinflammation: Aquaporin-4 autoimmunity and 2) Topic of the month: Updates in tele-neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Melanie Ward interviews Dr. Vanda Lennon about her Neurology: Neuroimmunology & Neuroinflammation paper on aquaporin-4 autoimmunity. Dr. Ted Burns is interviewing Kathy Pieper for our "What's Trending" feature of the week about you tube videos. In the next part of the podcast Dr. Andy Southerland interviews Dr. Kevin Barrett about the topic of updates in telestroke. The participants had nothing to disclose except Drs. Lennon, Burns, Pieper, Southerland and Barrett.Dr. Lennon receives research support from the NIH.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Kathy Pieper is Managing Editor, Neurology®.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Kevin Barrett serves as an Associate Editor of Neurohospitalist; serves as an editorial board member of Neurology; and receives research support from the NIH.NO CME WILL BE OFFERED THIS WEEK.

1) Migraine and risk of stroke in older adults and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Teshamae Monteith about her paper on migraine and risk of stroke in older adults. Dr. Adam Numis is reading our e-Pearl of the week about neurosyphilis. In the next part of the podcast Dr. Alberto Espay interviews Dr. Keith Josephs about his Frontiers in Neuroscience Lecture at the AAN Meeting about the topic of antemortem signatures of neurodegenerative proteinopathies. The participants had nothing to disclose except Drs. Southerland, Monteith, Numis, Espay and Josephs.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Monteith serves as an editorial advisory board member for Neurology Now; and receives research support from the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.

1) Opioids for chronic non-cancer pain and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Drs. Stephen Nadeau and Gary Franklin about their papers on opioids for chronic non-cancer pain and the policy behind prescribing them. Dr. Adam Numis is reading our e-Pearl of the week about vaccinations and seizures. In the next part of the podcast Dr. Alberto Espay interviews Dr. Virginia Lee about her Frontiers in Neuroscience Lecture at the AAN Meeting about the topic of transmission of alpha-Synuclein in Parkinson disease: Pathogenesis and implications for therapy. The participants had nothing to disclose except Drs. Burns, Nadeau, Franklin, Numis, Espay and Lee.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Nadeau served on the DSMB for the National Institute of Neurological Disorders and Stroke and National Institute of Child Health and Human Development funded Interdisciplinary Comprehensive Arm Rehab Evaluation, DSMB ; served as an Associate Editor of the Journal of the International Neuropsychological Society; received honoraria and funding for travel for an International Neuropsychological Society meeting; received funding for travel for an American Neuropsychiatric Association meeting; receives royalties from the publication of the book The Neural Architecture of Grammar ; and receives research support from a VA Rehabilitation R&D Grant and University of Florida McKnight Brain Institute Brain and Spinal Cord Injury Research Trust Fund Grant.Dr. Franklin serves as an editorial board member of Neurology® Levels of Evidence Team and Neuroepidemiology; is a consultant for the California State Compensation Insurance Fund and receives research support from the Centers for Disease Control and Prevention (CDC).Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Lee serves as an editorial board member of Laboratory Investigation, Neurorehabilitation and Neural Repair, NeuroSignals, Neuron, Experimental Neurology, Science Magazine; receives research support from Ware Benaroya and the NIH; receives revenue for the following patent: "Compositions and Methods for Producing and Using Homogeneous Neuronal Cell Transplants" Penn G1120, Patent # 5,792,900.

1) CIDP diagnostic pit-falls and perception of treatment benefits and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michelle Mauermann interviews Dr. Jeffrey Allen about his paper on chronic inflammatory demyelinating polyneuropathy diagnostic pit-falls and perception of treatment benefits. Dr. Adam Numis is reading our e-Pearl of the week about exam findings in hemifacial spasms. In the next part of the podcast Dr. Alberto Espay interviews Dr. Howard Weiner about his Frontiers in Neuroscience Lecture at the AAN Meeting about the topic of immune mechanisms in neurologic diseases. The participants had nothing to disclose except Drs. Mauermann, Allen, Numis, Espay and Weiner.Dr. Mauermann receives research support from ISIS Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc. and the NIH.Dr. Allen is a consultant for AxelaCare and CSL Behring.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Weiner is a consultant for Biogen Idec, Novartis, Merck Serono, Sanofi-aventis, Teva Pharmaceutical Industries Ltd. and Therapix Biosciences Ltd.; served on the advisory board for The Guthy Jackson Charitable Foundation, Teva Pharmaceutical Industries Ltd., Biogen Idec, Novartis, Sanofi-aventis; receives research support from EMD, Merck Serono, National Multiple Sclerosis Society, and the NIH.

Josep O. Dalmau, Editor of Neurology: Neuroimmunology & Neuroinfammation introduces the podcast inverview. Dr. Laura Benjamin interviews Dr. Don Gilden about his paper Widespread arterial infection by varicella zoster virus explains refractory giant cell arteritis.J. Damlau is the editor of Neurology: Neuroimmunology & Neuroinflammation, is on the editorial board for Neurology UpToDate, holds patents for and receives royalties from Ma2 autoantibody test, NMDA receptor autoantibody test, GABA(B) receptor autoantibody test, GABA(A) receptor autoantibody test, DPPX autoantibody test, IgLON5 autoantibody test, received research support from Euroimmun, NIH, Fondo de Investigaciones Sanitarias de la Seguridad Social (Spanish Government); L. Benjamin reports no disclosures; D. Gilden is a senior Associate editor for Journal of NeuroVirology, is on the editorial board for In Vivio, Journal of Virology, Scientific American Medicine, Virus Genes, Neurology, Journal of the Neurological Sciences, received research support from NIH;

1) Aerobic training and post-exercise protein in facioscapulohumeral muscular dystrophy and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Erik Ensrud interviews Dr. Grete Andersen about her paper on aerobic training and post-exercise protein in facioscapulohumeral muscular dystrophy. Dr. Adam Numis is reading our e-Pearl of the week about non-invasive imaging of arterial dissection with MRI. In the next part of the podcast Dr. Alberto Espay interviews Dr. Stefan Pulst about his George C. Cotzias Lecture at the AAN Meeting about the topic of degenerative ataxias: From genes to therapies. The participants had nothing to disclose except Drs. Ensrud, Numis, Espay and Pulst.Dr. Ensrud serves on the data safety monitoring board for phase II trial of methotrexate in myastenia gravis; is a consultant for Skulpt/Convergence Medical Devices and FDA; received honoraria and funding for travel from Osler Institute; received funding for travel from American Association of Physical Medicine and Rehabilitation; and received honoraria from American Association of Neuromuscular and Electrodiagnostic Medicine.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Pulst serves as Editor-in-Chief of Current Genomics; serves as Editor of Neurology® Genetics; serves as an editorial board member of Journal of Cerebellum, NeuroMolecular Medicine, Continuum, Experimental Neurology, Neurogenetics, and Nature Clinical Practice Neurology; is author on patents re: Nucleic acids encoding ataxin-2 binding proteins; Nucleic acid encoding Schwannomin-binding-proteins and products related thereto; Transgenic mouse expressing a polynucleotide encoding a human ataxin-2 polypeptide; Methods of detecting spinocerebellar ataxia-2 nucleic acids; Nucleic acid encoding spinocerebellar ataxia-2 and products related thereto; Schwannomin-binding-proteins; and Compositions and methods for spinocerebellar ataxia; receives royalties from the publications of the books The Ataxias, Genetics in Neurology, Genetics of Movement Disorders, Neurogenetics, and Molecular Genetic Testing in Neurology, 2nd–5th ed.; serves on the speakers' bureau for Athena Diagnostics; receives research support from the NIH and the National Ataxia Foundation; receives license fee payments from Cedars-Sinai Medical Center; and has provided expert testimony in a medico-legal case.

Inflammatory myopathy. Lesson of the Week interviews from May 2015.